Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Santhera Pharmaceuticals AG

www.santhera.com

Latest From Santhera Pharmaceuticals AG

Santhera Shares Sink On Duchenne Setback in Europe

Hopes were high for an expanded approval of Raxone but the CHMP's negative opinion has left the Swiss company's stock battered and bruised.

Policy & Regulation Companies

Not Just Herceptin Biosimilar: Additional 12 Drugs Set For EU Marketing Approval After CHMP Nod

New treatments for plaque psoriasis and ovarian and prostate cancer join the first Herceptin biosimilar and several other products in garnering recommendations for EU marketing approval at September's meeting of EMA's key scientific committee, the CHMP. No decision was taken on Roche’s new MS drug, Ocrevus, and earlier negative opinions of three other products were upheld.

Europe Approvals

Pipeline Watch: Phase III Starts With Fasinumab, Varlitinib

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Pipeline Watch Approvals

Duchenne Development: Data Sharing May Enable Trials To Move Beyond Six-Minute Walk

Repeated trial failures in this rare disease space have given birth to new alliances – one backed by Critical Path and the other by the CureDuchenne advocacy group – that aim to model disease progression much more accurately through data sharing and rigorous analysis.

Clinical Trials Drug Approval Standards
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Graffinity Pharmaceuticals AG
  • MyoContract Pharmaceutical Research Ltd.
  • Graffinity Pharmaceutical Design GMBH
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Switzerland
  • Parent & Subsidiaries
  • Santhera Pharmaceuticals AG
  • Senior Management
  • Thomas Meier, PhD, CEO
    Christoph Rentsch, CFO
    Gunther Metz, EVP, Head Bus. Dev.
    Kristina Sjöblom Nygren, CMO & EVP, Head Dev.
  • Contact Info
  • Santhera Pharmaceuticals AG
    Phone: (41) 61 906 89 50
    Hammerstrasse 49
    Liestal, CH-4410
    Switzerland
Advertisement
Advertisement
UsernamePublicRestriction

Register